Cormark Brokers Decrease Earnings Estimates for Curaleaf

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Research analysts at Cormark lowered their FY2024 earnings estimates for Curaleaf in a report released on Thursday, November 7th. Cormark analyst J. Pytlak now anticipates that the company will post earnings of ($0.27) per share for the year, down from their previous forecast of ($0.25). Cormark has a “Hold” rating on the stock. The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Cormark also issued estimates for Curaleaf’s FY2025 earnings at ($0.19) EPS.

Separately, Needham & Company LLC reissued a “buy” rating and set a $6.25 price objective on shares of Curaleaf in a research note on Thursday, August 8th.

Curaleaf Trading Down 22.1 %

OTCMKTS:CURLF opened at $1.66 on Monday. Curaleaf has a one year low of $1.64 and a one year high of $6.40. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.09 and a quick ratio of 0.50. The company’s 50-day simple moving average is $2.95 and its 200 day simple moving average is $3.77. The firm has a market capitalization of $1.08 billion, a P/E ratio of -5.72 and a beta of 0.86.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.